FEATURED EDITORIAL
Part I of this series focuses on the evidentiary shift of how NAMs may change the architecture of evidence and how that transition unfolds.
- Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies
- The Future Of Cancer Drug Discovery Is Targeted Immune Activation
- Will 2027 See A Meteoric Rise Of Programmable Nanomedicine?
- A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials
- Emerging Fields In Immunology: New Frontiers For Therapeutic Discovery
- Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections
- It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials
FEATURED APPLICATION CONTENT
-
A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.
-
Antibody-oligonucleotide conjugates introduce conjugation and purification challenges that standard ADC process development wasn't designed to solve. This white paper details practical approaches for each.
-
Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
- A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials
- What The China Biotech Debate Reveals About U.S. Drug Discovery
- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
- Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Creative Biolabs Expands Integrated AI-Driven Chemical Synthesis Platforms To Accelerate Next-Generation Drug Discovery
- Alebund Pharmaceuticals Announces FDA Clearance Of IND Application For AP308 For The Treatment Of IgA Nephropathy
- Acepodia Announces FDA Clearance Of IND Application For ACE723, A Novel Dual-Payload Antibody-Drug Conjugate
- Kali Therapeutics Receives U.S. FDA Clearance For KT501 Investigational New Drug Application
- Nuffield Department Of Medicine At The University Of Oxford And 2U Launch New Program In AI-Driven Drug Discovery
- BenchSci Announces Two-Year Enterprise Agreement With Argenx To Advance AI-Driven Preclinical Drug Discovery
- Insilico Medicine Included In The HKEX Tech 100 Index, Drawing Attention To Opportunities In AI Value Chain
- NorthStrive Biosciences Expands AI-Driven Drug Discovery Program With Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination For Potential Cardiac Disease And Obesity Therapeutic Applications
- QC Ware And IonQ Demonstrate High-Precision Hybrid Quantum Workflow For Drug Discovery
- Weave Bio Announces Collaboration With Takeda To Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
ARCHIVED NEWSLETTER
- 09.08.26 -- Which Discovery Technologies Help Solve Degrader Assay Gaps
- 09.05.26 -- Drug Discovery Online Best Of August
- 09.03.26 -- How Imaging And Translational Models Solutions Are Accelerating Discovery
- 09.01.26 -- Shelf Stable Bioprinted Human Tissue Models: A 2026 Nucleate Boston Activator Cohort Interview With Carlos Ezio, CEO, Criocore
- 08.27.26 -- Could These Assay & Screening Solutions Improve Your Workflow?
